NCT03863223
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with history of anti-cancer therapy for MBC, with the exception of one prior hormonal regimen or trastuzumab (Herceptin) used before or after surgery
https://ClinicalTrials.gov/show/NCT03863223